CA-HYPERICE
18.1.2024 15:01:36 CET | Business Wire | Press release
Hyperice, a high-performance wellness brand and innovator of percussion, dynamic air compression, thermal, vibration, and contrast therapy technology, filed 16 additional lawsuits in Federal Court on Tuesday, January 16th, 2024 against Sharper Image, HoMedics, Ekrin Athletics, and more than a dozen others, including retailers CVS, Costco, Walgreens and Kohl’s, related to the sale of percussive massage guns, alleging infringement of Hyperice's patented percussion massage technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240118052531/en/
Hypervolt 2 Pro from Hyperice (Photo: Business Wire)
In the lawsuits, which targeted both massage gun direct sellers and numerous retailers, Hyperice asserted its recently-issued U.S. Patent No. 11,857,482, which claims technology dating back to 2013 that is utilized in nearly all massage guns on the market today. Hyperice made national headlines in 2018, launching the Hypervolt, the world’s first “modern-day” massage gun, featuring a brushless motor system, variable speed settings, and QuietGlide® technology. The success and rapid scale of the Hypervolt led to an influx of massage gun brands entering the market to replicate this technology, including the aforementioned parties. Hyperice sells numerous products embodying the patented technology, including its Hypervolt Go 2, Hypervolt 2, and Hypervolt 2 Pro.
In the lawsuits, Hyperice contends that several Sharper Image, HoMedics, Ekrin Athletics, and other products infringe Hyperice’s IP, including but not limited to the Sharper Image Powerboost line, and the Ekrin Athletics massage guns, along with the HoMedics, TRAKK, Eleeels, Vybe, Osaki, LifePro, and other lines of massage guns. In the coming weeks, Hyperice intends to file additional lawsuits against many other sellers and retailers believed to have infringed on this patent. Hyperice has also filed a series of related patent applications to further enhance the scope and scale of protection around the percussion category at large.
This announcement follows legal action taken by Hyperice on January 3rd, where Hyperice sued Therabody, maker of the Theragun and TheraFace products, in Federal Court for patent infringement, contending that numerous Therabody products infringe, including Theragun Elite, Theragun PRO, Theragun Prime, Theragun Mini, Theragun Sense, and TheraFace PRO. Hyperice will add additional products in the lawsuit against Therabody including the Theragun Relief, and any new products that are believed to infringe upon the recently issued patent.
“At Hyperice’s core, we develop innovative products and technologies to enhance recovery, performance, and longevity for consumers worldwide,” said Jim Huether, Hyperice CEO. “For any company working to lead and grow a new and emerging market in the technology sector, the inventive process is extremely important. As such, we hold innovation in high regard and safeguard our products and technology by obtaining patents. There are hundreds of millions of dollars of massage guns sold every year in the U.S. alone, and we believe that a vast majority of these massage guns infringe this patent. We will use aggressive legal actions against all infringers to reinstill credibility of the percussion market.”
In 2023, the massage gun market was valued at USD 542.6 million and is expected to reach well over USD 1 billion over the coming years1 with growth being fuelled by the advancement of technology, consumer’s understanding of the benefits, and prioritization of overall wellness and self-care.
“The actions that we have taken today are one part of a larger legal strategy to protect our intellectual property rights. We intend to take additional actions in the coming days and weeks to ensure that our innovative line of percussion massage guns is protected,” said Jon Howell, General Counsel at Hyperice.
UNMATCHED TECHNOLOGY AND INNOVATION
Hyperice dedicates considerable resources to research, develop, and protect its intellectual property. The brand holds hundreds of patents worldwide and will continue to take an assertive approach to protecting all aspects of its intellectual property. In 2021, Hyperice was recognized by Fast Company as one of the world’s most innovative companies. Hyperice has also attracted some of the world’s most prominent athletes and sports leagues as partners and investors, including Patrick Mahomes, Erling Haaland, Jayson Tatum, Naomi Osaka, Rory McIlroy, the NFL, MLB, NBA, UFC, and PGA TOUR.
Hyperice is represented in the lawsuit by Lawrence LaPorte of Lewis Brisbois Bisgaard & Smith LLP, Ben Herbert of Miller Barondess, LLP, and Brian Arnold, Associate General Counsel and Head of IP at Hyperice. Mr. Arnold was previously a patent litigation partner at several firms including Kirkland & Ellis LLP and, most recently, Lewis Roca Rothgerber Christie LLP.
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues, and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance, and workplace wellness on a global scale. For more information, visit hyperice.com.
_______________
1 Future Market Insights: Global Massage Gun Market Outlook (2023 to 2033)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240118052531/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom